Amphetamines, growth hormone and narcolepsy.
1 Plasma amphetamine and growth hormone levels have been measured in eight normal and twenty-six narcoleptic subjects following a single dose of (+)-amphetamine (20 mg) or (-)-amphetamine (20 mg) by mouth. 2 Peak plasma levels and the shape of the plasma amphetamine-time curve were similar with both isomers in normal and narcoleptic subjects. 3 In most normal subjects both (+)-and (-)-amphetamine (20 mg) caused an increase in the plasma concentration of growth hormone. The two isomers were approximately equipotent in this respect. Neither (+)- nor (-)-amphetamine (20 mg) caused an increase in plasma growth hormone concentration in narcoleptics. 4 Following amphetamine (30 mg), two of six narcoleptic subjects had an increase in plasma growth hormone concentration. 5 Levodopa (250 mg) with (-)-alpha-methyldopa hydrazine 25 mg (Sinemet) by mouth, caused a rise in plasma growth hormone concentration in most normal subjects. The magnitude of the Sinemet-induced rise in plasma growth hormone concentration in narcoleptics was less than in normal subjects.
D000328:Adult; D000368:Aged; D000661:Amphetamine / Q000097:blood / Q000494:pharmacology*; D001143:Arousal / Q000187:drug effects; D002997:Clomipramine / Q000494:pharmacology; D003913:Dextroamphetamine / Q000097:blood / Q000494:pharmacology*; D004347:Drug Interactions; D004361:Drug Tolerance; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008750:Methyldopa / Q000494:pharmacology; D008875:Middle Aged; D009290:Narcolepsy / Q000097:blood* / Q000503:physiopathology; D013997:Time Factors
D007980:Levodopa; D008750:Methyldopa; D013006:Growth Hormone; D000661:Amphetamine; D002997:Clomipramine; D003913:Dextroamphetamine